Abstract
Neoadjuvant treatment of early and locally advanced cancer is considered to be an integral part of modern anticancer treatment. Its advantage is comparable to adjuvant treatment in terms of disease-free survival and survival.
Try neoadjuvant treatment with operatively advanced disease, downstaging, find the biological properties of the tumor including prognostic information, reduce the radicality of the operation and wait for the determination of genetic tests (BRCA 1.2). In recent years it has been possible to administer high-risk patients with an early stage of the disease in an effort to give pathological complete remissions, which in particular in triple negative and HER2 positive tumors may be a prognostic factor in the risk of disease recurrence.
By default, administration of chemotherapeutic regimens for the composition of anthracyclines, taxanes, and HER2-positive cancers is targeted therapy, including hormonal therapy.